In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
C-Suite Speaks Commercial Coronavirus COVID-19

Setting Ego Aside To Better Human Health

Interview With INOVIO's Kate Broderick

  • Interviews

Executive Summary

Kate Broderick, SVP of research and development at INOVIO and one of In Vivo’s 2021 rising leaders, is hopeful that greater collaboration will be the lasting effect of COVID-19.

You may also be interested in...



Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work

Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions. 

Accessing Venture Debt From The EIB

Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.

Table

View full table

Topics

Related Companies

Tags:
C-Suite Speaks Commercial Coronavirus COVID-19
Latest Headlines

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

Six New Molecules By 2030 – J&J’s Neuroscience Strategy

China VBP, Localization And Other Strategies - How Far And Which Way?

See All
UsernamePublicRestriction

Register

IV124790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By